Brind.
  1. Ascendis Pharma's TransCon CNP is under U.S. FDA priority review, and the company aims to fulfill Vision 2030.

Novo Nordisk and Ascendis Pharma Terminate Collaboration on TransCon Products

2 reports, 2 independent Updated Sep 22
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

The collaboration between Novo Nordisk and Ascendis Pharma regarding TransCon products has been terminated. Ascendis Pharma has regained exclusive rights to develop, manufacture, and commercialize TransCon technology-based products for metabolic and cardiovascular diseases. This includes once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide, intended for obesity and type 2 diabetes.

From foreignpolicyjournal.com, insidermonkey.com

Why it matters

Some supportBrind's analysis of the reports

The move signals a significant strategic shift for Ascendis Pharma, allowing the company to advance its obesity and type 2 diabetes programs independently. Bringing these rights in-house concentrates both the potential financial upside and the full weight of development and commercialization costs onto Ascendis Pharma's balance sheet.

Ascendis Pharma's TransCon CNP is currently under U.S. FDA priority review, and the company aims to fulfill Vision 2030.

From foreignpolicyjournal.com

Who's involved

  • Novo NordiskDanish pharmaceutical company whose collaboration rights were relinquished

Keep exploring

Part of

Ascendis Pharma's TransCon CNP is under U.S. FDA priority review, and the company aims to fulfill Vision 2030. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped